The Preclinical Assets Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Preclinical Assets Market?
The preclinical assets market has experienced robust growth recently. The market size is projected to increase from $5.87 billion in 2024 to $6.4 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 9.1%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Preclinical Assets Industry?
The Preclinical Assets Global Market Report 2024 projects that by 2029, the market will reach $9.3 billion, growing at a compound annual growth rate (CAGR) of 9.8%.
Download Your Free Sample of the 2025 Preclinical Assets Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Preclinical Assets Market?
The key drivers in the preclinical assets market are:
• The advancement and application of precision medicine and personalized therapies
• Incorporation of AI and machine learning in preclinical research
• Expansion of biobanking
• Enhanced focus on rare diseases and corresponding governmental initiatives and funding.
Global Market Segmentation: Identifying Major Preclinical Assets Industry Segments
The preclinical assets market covered in this report is segmented –
1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users
Pre-order the 2025 Preclinical Assets Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Preclinical Assets Market?
The key trends in the preclinical assets market are:
• The integration of AI and machine learning is becoming a significant trend in preclinical assets market.
• Biobanking expansion is a rising trend in the sector.
• There is an increasing focus on rare diseases in the market.
• The automation and high throughput screening are emerging trends shaping the future of the market.
Who Are the Top Competitors & Leading Players in the Preclinical Assets Market?
The major players in the preclinical assets market are:
• Laboratory Corporation of America
• IQVIA Inc
Regional Dominance: Which Area Leads the Global Preclinical Assets Market?
North America was the largest region in the preclinical assets market in 2024
